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ciency, although he had no family members who had a history of
thrombosis. His protein C (PC) level was within normal range, and
both anti -cardiolipin antibodies and lupus anticoagulant were nega-
tive, excluding PC deficiency or anti -phospholipid syndrome.
A regular dose of edoxaban was not effective for preventing VTE
recurrence, which might be attributable to the patient’s poor drug
adherence. In addition, a high dose of apixaban but not edoxaban
was available for the treatment of acute VTE. Therefore, he was
administered a high dose of 20 mg apixaban for 7 days for acute
VTE, with no heparin bridging or hospitalization, following admini-
stration of a regular dose of 10 mg apixaban. Anti -depressants,
which may be a risk factor for the recurrence of VTE, were contin-
ued because his depressive state was stabilized by these drugs. His
right leg swelling gradually improved and follow-up venous echog-
raphy after 12 days revealed that the acute thrombus in the IVC to
the right femoral vein was almost resolved, and showed only mural
thrombus (Figure 2B). It is planned that he will continue to receive
apixaban therapy for life, as long as he does not experience major
bleeding.
DISCUSSION
In this case, a high dose of apixaban was effective for the treat-
ment of VTE in a patient with PS deficiency who received edoxaban
therapy.
PS serves as a cofactor for activated PC, which inactivates
procoagulant factors Va and a, reducing thrombin generation
and enhancing fibrinolysis. PS can also directly inhibit prothrom-
bin activation via interactions with other coagulation factors (6, 7).
Some genetic variations of the PS gene have been identified as
genetic risk factors for VTE, including amino acid substitution of
Glu(GAG) for Lys-155(AAG), known as PS Tokushima (1, 8),
with an odds ratio of 4.72 (9, 10).
Congenital PS deficiency has been identified in 1-7.5% of patients
with VTE and in 0.03-0.13% of the general Caucasian population.
However, it has been reported that there is a higher prevalence in
the Japanese population, both for VTE patients (12.7%) and the
general population (0.48-0.63%) (11-13). PS deficiency is the most
frequent congenital thrombophilia in Japanese people ; therefore,
we must understand this thrombophilia, and that patients with PS
deficiency have an increased risk of VTE and a necessity for
prophylactic use of anticoagulants for recurrent VTE (11, 12).
For the treatment of VTE in Japan, unfractionated heparin fol-
lowed by warfarin has been historically administered. However,
vitamin K antagonists could suppress the synthesis of vitamin K-
dependent anticoagulation factors, including PC and PS, in addition
to coagulation, factors of prothrombin factor,, and X. Thus,
further inhibition of PS could be worsen VTE in patients with PS
deficiency. We previously showed that warfarin therapy decreased
PS activity to 46% and PC activity to 62%, but that edoxaban therapy
maintained PS and PC activity to 90% and 93%, respectively, in
patients with VTE (14). Thus, DOACs could be preferable therapy
for VTE in patients with PS/PC deficiency. In theory, DOACs
should be effective in patients with thrombophilia. However,
there has been no clinical trial showing the effects and safety of
DOACs in patients with PS deficiency. There have been some
reports of PS deficiency complicated with VTE that were success-
fully treated with rivaroxaban (15) (16),and some recurrent cases of
deep vein thrombosis after rivaroxaban treatment (17). A small
subset of patients with thrombophilic disorders (5−7%) were
included in the EINSTEIN rivaroxaban trial (3) and the AMPLIFY
apixaban trial (5), but no specific information was recorded to
identify the type of hypercoagulable disorder. The guideline
from the American College of Chest Physicians does not describe
the treatment of VTE in patients with thrombophilia, but describes
thrombophilic disorders as a risk factor for recurrent VTE (18).
The patient had poor drug adherence and recurrent VTE during
edoxaban therapy. Recurrent VTE was mostly related to poor drug
adherence, which highlights the important role of regular DOACs
in high-risk patients. In addition, he had received anti -depressants
for years. Depression and anti -depressant therapy have been re-
ported to be risk factors for VTE (19). Furthermore, he had previ-
ously had an IVC filter implanted, and it has been reported that
these filters do not prevent VTE occurrence (20), indicating that
Figure 2. Venous echographic imaging of VTE focused on the right femoral vein before apixaban treatment (A) and after apixaban treatment (B).
Filled squares indicate poor imaging sites with venous echography
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the IVC filter itself may generate thrombi. We previously reported
that IVC filter implantation could cause endovascular damage and
fibrin formation, resulting in thrombus formation (21). Activation
of the extrinsic pathway by endovascular damage from mechanical
stress and activation of the intrinsic pathway triggered by IVC filter
contact with  factor might enhance thrombus formation. In this
patient, these risk factors, in addition to PS deficiency, may have
contributed to the recurrence of VTE.
DOACs are generally preferred over warfarin for the acute
treatment of VTE ; however, there is no specific guideline for use in
patients with inherited thrombophilia. Additional evaluation of
DOAC use in patients with inherited thrombophilia is necessary to
provide further evidence.
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